Baidu
map

Ann Pharmacother:如何降低非ICU患者抑酸药物不合理使用?

2017-07-03 何娜 环球医学资讯

超过30%的非重症监护室(ICU)患者被不恰当地处方应激性溃疡预防(SUP)药物,导致不必要的不良事件,以及经济负担的增加。2017年7月,发表在《Ann Pharmacother.》的一项回顾性干预研究表明,药师和住院医合作策略能降低非ICU患者抑酸药物不恰当使用。

超过30%的非重症监护室(ICU)患者被不恰当地处方应激性溃疡预防(SUP)药物,导致不必要的不良事件,以及经济负担的增加。2017年7月,发表在《Ann Pharmacother.》的一项回顾性干预研究表明,药师和住院医合作策略能降低非ICU患者抑酸药物不恰当使用。

目的:研究者所在医院的非危重症患者预防性使用抑酸疗法(AST)的趋势有所增加,因此促使研究者开始降低非ICU患者对AST的不恰当使用。

方法:该研究为一项回顾性干预研究,包括指南的制定、对住院医服务教育以及临床药师干预。考虑纳入所有接受住院医服务治疗,且初始使用AST的非ICU成人患者。主要结局指标为处方不恰当AST的住院患者天数比例比较。次要结局指标包括出院患者使用不恰当AST的比例和药物获得成本、成功药物干预、住院医干预、难辨梭状芽孢杆菌感染(CDI)或胃肠道(GI)出血,以及通过药学干预避免的药物成本的比较。

结果:历史组61例患者,干预组81例患者。干预导致不恰当AST患者天数绝对值降低31%,出院患者使用不恰当AST绝对降低24%。23次干预成功。没有CDI病例,有1例GI出血病例。干预导致每例患者的药物获得成本降低87%。

结论临床药师和住院医服务合作能显着降低非ICU患者AST的不恰当使用。

专家点评:PPI目前存在过度使用的情况,重症监护室、重症监护室转入普通病房、普通病房患者出院三个环节均可以进行干预以促进合理用药。

原始出处
Belfield, K. D., et al. Impact of A Collaborative Strategy to Reduce the Inappropriate Use of Acid Suppressive Therapy in Non-Intensive Care Unit Patients.Ann Pharmacother. 2017 Jul;51(7):577-583. doi: 10.1177/1060028017698797. Epub 2017 Mar 9.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1651181, encodeId=47a116511816c, content=<a href='/topic/show?id=924c5499576' target=_blank style='color:#2F92EE;'>#抑酸药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54995, encryptionId=924c5499576, topicName=抑酸药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b25424139161, createdName=liuxiaona, createdTime=Thu Apr 26 15:53:00 CST 2018, time=2018-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1771678, encodeId=8d8a1e7167848, content=<a href='/topic/show?id=0c913884975' target=_blank style='color:#2F92EE;'>#合理使用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38849, encryptionId=0c913884975, topicName=合理使用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ed3c38340222, createdName=doctorzheng, createdTime=Tue Mar 27 00:53:00 CST 2018, time=2018-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787285, encodeId=86811e8728584, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sun Jul 30 01:53:00 CST 2017, time=2017-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908282, encodeId=7f43190828266, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Fri Feb 16 14:53:00 CST 2018, time=2018-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996014, encodeId=8bf8199601470, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Fri Nov 03 08:53:00 CST 2017, time=2017-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1546053, encodeId=6c2f1546053d7, content=<a href='/topic/show?id=fdec54994f5' target=_blank style='color:#2F92EE;'>#抑酸药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54994, encryptionId=fdec54994f5, topicName=抑酸药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=410e13859549, createdName=passed water, createdTime=Wed Jul 05 07:53:00 CST 2017, time=2017-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1595354, encodeId=dd521595354c5, content=<a href='/topic/show?id=44b993e977' target=_blank style='color:#2F92EE;'>#ICU患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9379, encryptionId=44b993e977, topicName=ICU患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=003c18235152, createdName=piaojinhua, createdTime=Wed Jul 05 07:53:00 CST 2017, time=2017-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=218212, encodeId=3b3b2182122d, content=学习了学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7SEMbIqicph9XjjB508YwgovWXrJrvXs6oQCG2x4iaUOS1ouvNLf8dRtkwfFsMN1sRUP5e5rbr7eUJPS8Gdt0aOq/0, createdBy=99cf2073595, createdName=蒋宇, createdTime=Mon Jul 03 20:06:12 CST 2017, time=2017-07-03, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1651181, encodeId=47a116511816c, content=<a href='/topic/show?id=924c5499576' target=_blank style='color:#2F92EE;'>#抑酸药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54995, encryptionId=924c5499576, topicName=抑酸药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b25424139161, createdName=liuxiaona, createdTime=Thu Apr 26 15:53:00 CST 2018, time=2018-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1771678, encodeId=8d8a1e7167848, content=<a href='/topic/show?id=0c913884975' target=_blank style='color:#2F92EE;'>#合理使用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38849, encryptionId=0c913884975, topicName=合理使用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ed3c38340222, createdName=doctorzheng, createdTime=Tue Mar 27 00:53:00 CST 2018, time=2018-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787285, encodeId=86811e8728584, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sun Jul 30 01:53:00 CST 2017, time=2017-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908282, encodeId=7f43190828266, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Fri Feb 16 14:53:00 CST 2018, time=2018-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996014, encodeId=8bf8199601470, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Fri Nov 03 08:53:00 CST 2017, time=2017-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1546053, encodeId=6c2f1546053d7, content=<a href='/topic/show?id=fdec54994f5' target=_blank style='color:#2F92EE;'>#抑酸药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54994, encryptionId=fdec54994f5, topicName=抑酸药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=410e13859549, createdName=passed water, createdTime=Wed Jul 05 07:53:00 CST 2017, time=2017-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1595354, encodeId=dd521595354c5, content=<a href='/topic/show?id=44b993e977' target=_blank style='color:#2F92EE;'>#ICU患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9379, encryptionId=44b993e977, topicName=ICU患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=003c18235152, createdName=piaojinhua, createdTime=Wed Jul 05 07:53:00 CST 2017, time=2017-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=218212, encodeId=3b3b2182122d, content=学习了学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7SEMbIqicph9XjjB508YwgovWXrJrvXs6oQCG2x4iaUOS1ouvNLf8dRtkwfFsMN1sRUP5e5rbr7eUJPS8Gdt0aOq/0, createdBy=99cf2073595, createdName=蒋宇, createdTime=Mon Jul 03 20:06:12 CST 2017, time=2017-07-03, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1651181, encodeId=47a116511816c, content=<a href='/topic/show?id=924c5499576' target=_blank style='color:#2F92EE;'>#抑酸药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54995, encryptionId=924c5499576, topicName=抑酸药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b25424139161, createdName=liuxiaona, createdTime=Thu Apr 26 15:53:00 CST 2018, time=2018-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1771678, encodeId=8d8a1e7167848, content=<a href='/topic/show?id=0c913884975' target=_blank style='color:#2F92EE;'>#合理使用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38849, encryptionId=0c913884975, topicName=合理使用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ed3c38340222, createdName=doctorzheng, createdTime=Tue Mar 27 00:53:00 CST 2018, time=2018-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787285, encodeId=86811e8728584, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sun Jul 30 01:53:00 CST 2017, time=2017-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908282, encodeId=7f43190828266, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Fri Feb 16 14:53:00 CST 2018, time=2018-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996014, encodeId=8bf8199601470, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Fri Nov 03 08:53:00 CST 2017, time=2017-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1546053, encodeId=6c2f1546053d7, content=<a href='/topic/show?id=fdec54994f5' target=_blank style='color:#2F92EE;'>#抑酸药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54994, encryptionId=fdec54994f5, topicName=抑酸药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=410e13859549, createdName=passed water, createdTime=Wed Jul 05 07:53:00 CST 2017, time=2017-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1595354, encodeId=dd521595354c5, content=<a href='/topic/show?id=44b993e977' target=_blank style='color:#2F92EE;'>#ICU患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9379, encryptionId=44b993e977, topicName=ICU患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=003c18235152, createdName=piaojinhua, createdTime=Wed Jul 05 07:53:00 CST 2017, time=2017-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=218212, encodeId=3b3b2182122d, content=学习了学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7SEMbIqicph9XjjB508YwgovWXrJrvXs6oQCG2x4iaUOS1ouvNLf8dRtkwfFsMN1sRUP5e5rbr7eUJPS8Gdt0aOq/0, createdBy=99cf2073595, createdName=蒋宇, createdTime=Mon Jul 03 20:06:12 CST 2017, time=2017-07-03, status=1, ipAttribution=)]
    2017-07-30 jj000001
  4. [GetPortalCommentsPageByObjectIdResponse(id=1651181, encodeId=47a116511816c, content=<a href='/topic/show?id=924c5499576' target=_blank style='color:#2F92EE;'>#抑酸药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54995, encryptionId=924c5499576, topicName=抑酸药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b25424139161, createdName=liuxiaona, createdTime=Thu Apr 26 15:53:00 CST 2018, time=2018-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1771678, encodeId=8d8a1e7167848, content=<a href='/topic/show?id=0c913884975' target=_blank style='color:#2F92EE;'>#合理使用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38849, encryptionId=0c913884975, topicName=合理使用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ed3c38340222, createdName=doctorzheng, createdTime=Tue Mar 27 00:53:00 CST 2018, time=2018-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787285, encodeId=86811e8728584, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sun Jul 30 01:53:00 CST 2017, time=2017-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908282, encodeId=7f43190828266, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Fri Feb 16 14:53:00 CST 2018, time=2018-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996014, encodeId=8bf8199601470, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Fri Nov 03 08:53:00 CST 2017, time=2017-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1546053, encodeId=6c2f1546053d7, content=<a href='/topic/show?id=fdec54994f5' target=_blank style='color:#2F92EE;'>#抑酸药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54994, encryptionId=fdec54994f5, topicName=抑酸药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=410e13859549, createdName=passed water, createdTime=Wed Jul 05 07:53:00 CST 2017, time=2017-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1595354, encodeId=dd521595354c5, content=<a href='/topic/show?id=44b993e977' target=_blank style='color:#2F92EE;'>#ICU患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9379, encryptionId=44b993e977, topicName=ICU患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=003c18235152, createdName=piaojinhua, createdTime=Wed Jul 05 07:53:00 CST 2017, time=2017-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=218212, encodeId=3b3b2182122d, content=学习了学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7SEMbIqicph9XjjB508YwgovWXrJrvXs6oQCG2x4iaUOS1ouvNLf8dRtkwfFsMN1sRUP5e5rbr7eUJPS8Gdt0aOq/0, createdBy=99cf2073595, createdName=蒋宇, createdTime=Mon Jul 03 20:06:12 CST 2017, time=2017-07-03, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1651181, encodeId=47a116511816c, content=<a href='/topic/show?id=924c5499576' target=_blank style='color:#2F92EE;'>#抑酸药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54995, encryptionId=924c5499576, topicName=抑酸药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b25424139161, createdName=liuxiaona, createdTime=Thu Apr 26 15:53:00 CST 2018, time=2018-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1771678, encodeId=8d8a1e7167848, content=<a href='/topic/show?id=0c913884975' target=_blank style='color:#2F92EE;'>#合理使用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38849, encryptionId=0c913884975, topicName=合理使用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ed3c38340222, createdName=doctorzheng, createdTime=Tue Mar 27 00:53:00 CST 2018, time=2018-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787285, encodeId=86811e8728584, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sun Jul 30 01:53:00 CST 2017, time=2017-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908282, encodeId=7f43190828266, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Fri Feb 16 14:53:00 CST 2018, time=2018-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996014, encodeId=8bf8199601470, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Fri Nov 03 08:53:00 CST 2017, time=2017-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1546053, encodeId=6c2f1546053d7, content=<a href='/topic/show?id=fdec54994f5' target=_blank style='color:#2F92EE;'>#抑酸药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54994, encryptionId=fdec54994f5, topicName=抑酸药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=410e13859549, createdName=passed water, createdTime=Wed Jul 05 07:53:00 CST 2017, time=2017-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1595354, encodeId=dd521595354c5, content=<a href='/topic/show?id=44b993e977' target=_blank style='color:#2F92EE;'>#ICU患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9379, encryptionId=44b993e977, topicName=ICU患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=003c18235152, createdName=piaojinhua, createdTime=Wed Jul 05 07:53:00 CST 2017, time=2017-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=218212, encodeId=3b3b2182122d, content=学习了学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7SEMbIqicph9XjjB508YwgovWXrJrvXs6oQCG2x4iaUOS1ouvNLf8dRtkwfFsMN1sRUP5e5rbr7eUJPS8Gdt0aOq/0, createdBy=99cf2073595, createdName=蒋宇, createdTime=Mon Jul 03 20:06:12 CST 2017, time=2017-07-03, status=1, ipAttribution=)]
    2017-11-03 yb6560
  6. [GetPortalCommentsPageByObjectIdResponse(id=1651181, encodeId=47a116511816c, content=<a href='/topic/show?id=924c5499576' target=_blank style='color:#2F92EE;'>#抑酸药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54995, encryptionId=924c5499576, topicName=抑酸药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b25424139161, createdName=liuxiaona, createdTime=Thu Apr 26 15:53:00 CST 2018, time=2018-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1771678, encodeId=8d8a1e7167848, content=<a href='/topic/show?id=0c913884975' target=_blank style='color:#2F92EE;'>#合理使用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38849, encryptionId=0c913884975, topicName=合理使用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ed3c38340222, createdName=doctorzheng, createdTime=Tue Mar 27 00:53:00 CST 2018, time=2018-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787285, encodeId=86811e8728584, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sun Jul 30 01:53:00 CST 2017, time=2017-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908282, encodeId=7f43190828266, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Fri Feb 16 14:53:00 CST 2018, time=2018-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996014, encodeId=8bf8199601470, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Fri Nov 03 08:53:00 CST 2017, time=2017-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1546053, encodeId=6c2f1546053d7, content=<a href='/topic/show?id=fdec54994f5' target=_blank style='color:#2F92EE;'>#抑酸药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54994, encryptionId=fdec54994f5, topicName=抑酸药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=410e13859549, createdName=passed water, createdTime=Wed Jul 05 07:53:00 CST 2017, time=2017-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1595354, encodeId=dd521595354c5, content=<a href='/topic/show?id=44b993e977' target=_blank style='color:#2F92EE;'>#ICU患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9379, encryptionId=44b993e977, topicName=ICU患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=003c18235152, createdName=piaojinhua, createdTime=Wed Jul 05 07:53:00 CST 2017, time=2017-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=218212, encodeId=3b3b2182122d, content=学习了学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7SEMbIqicph9XjjB508YwgovWXrJrvXs6oQCG2x4iaUOS1ouvNLf8dRtkwfFsMN1sRUP5e5rbr7eUJPS8Gdt0aOq/0, createdBy=99cf2073595, createdName=蒋宇, createdTime=Mon Jul 03 20:06:12 CST 2017, time=2017-07-03, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1651181, encodeId=47a116511816c, content=<a href='/topic/show?id=924c5499576' target=_blank style='color:#2F92EE;'>#抑酸药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54995, encryptionId=924c5499576, topicName=抑酸药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b25424139161, createdName=liuxiaona, createdTime=Thu Apr 26 15:53:00 CST 2018, time=2018-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1771678, encodeId=8d8a1e7167848, content=<a href='/topic/show?id=0c913884975' target=_blank style='color:#2F92EE;'>#合理使用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38849, encryptionId=0c913884975, topicName=合理使用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ed3c38340222, createdName=doctorzheng, createdTime=Tue Mar 27 00:53:00 CST 2018, time=2018-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787285, encodeId=86811e8728584, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sun Jul 30 01:53:00 CST 2017, time=2017-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908282, encodeId=7f43190828266, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Fri Feb 16 14:53:00 CST 2018, time=2018-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996014, encodeId=8bf8199601470, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Fri Nov 03 08:53:00 CST 2017, time=2017-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1546053, encodeId=6c2f1546053d7, content=<a href='/topic/show?id=fdec54994f5' target=_blank style='color:#2F92EE;'>#抑酸药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54994, encryptionId=fdec54994f5, topicName=抑酸药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=410e13859549, createdName=passed water, createdTime=Wed Jul 05 07:53:00 CST 2017, time=2017-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1595354, encodeId=dd521595354c5, content=<a href='/topic/show?id=44b993e977' target=_blank style='color:#2F92EE;'>#ICU患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9379, encryptionId=44b993e977, topicName=ICU患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=003c18235152, createdName=piaojinhua, createdTime=Wed Jul 05 07:53:00 CST 2017, time=2017-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=218212, encodeId=3b3b2182122d, content=学习了学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7SEMbIqicph9XjjB508YwgovWXrJrvXs6oQCG2x4iaUOS1ouvNLf8dRtkwfFsMN1sRUP5e5rbr7eUJPS8Gdt0aOq/0, createdBy=99cf2073595, createdName=蒋宇, createdTime=Mon Jul 03 20:06:12 CST 2017, time=2017-07-03, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1651181, encodeId=47a116511816c, content=<a href='/topic/show?id=924c5499576' target=_blank style='color:#2F92EE;'>#抑酸药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54995, encryptionId=924c5499576, topicName=抑酸药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b25424139161, createdName=liuxiaona, createdTime=Thu Apr 26 15:53:00 CST 2018, time=2018-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1771678, encodeId=8d8a1e7167848, content=<a href='/topic/show?id=0c913884975' target=_blank style='color:#2F92EE;'>#合理使用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38849, encryptionId=0c913884975, topicName=合理使用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ed3c38340222, createdName=doctorzheng, createdTime=Tue Mar 27 00:53:00 CST 2018, time=2018-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787285, encodeId=86811e8728584, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sun Jul 30 01:53:00 CST 2017, time=2017-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908282, encodeId=7f43190828266, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Fri Feb 16 14:53:00 CST 2018, time=2018-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996014, encodeId=8bf8199601470, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Fri Nov 03 08:53:00 CST 2017, time=2017-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1546053, encodeId=6c2f1546053d7, content=<a href='/topic/show?id=fdec54994f5' target=_blank style='color:#2F92EE;'>#抑酸药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54994, encryptionId=fdec54994f5, topicName=抑酸药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=410e13859549, createdName=passed water, createdTime=Wed Jul 05 07:53:00 CST 2017, time=2017-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1595354, encodeId=dd521595354c5, content=<a href='/topic/show?id=44b993e977' target=_blank style='color:#2F92EE;'>#ICU患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9379, encryptionId=44b993e977, topicName=ICU患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=003c18235152, createdName=piaojinhua, createdTime=Wed Jul 05 07:53:00 CST 2017, time=2017-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=218212, encodeId=3b3b2182122d, content=学习了学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7SEMbIqicph9XjjB508YwgovWXrJrvXs6oQCG2x4iaUOS1ouvNLf8dRtkwfFsMN1sRUP5e5rbr7eUJPS8Gdt0aOq/0, createdBy=99cf2073595, createdName=蒋宇, createdTime=Mon Jul 03 20:06:12 CST 2017, time=2017-07-03, status=1, ipAttribution=)]
    2017-07-03 蒋宇

    学习了学习了

    0

Baidu
map
Baidu
map
Baidu
map